<DOC>
	<DOCNO>NCT00572312</DOCNO>
	<brief_summary>The main purpose study find whether addition statin ( Atorvastatin ) dual renin-angiotensin-aldosterone system blockade involve angiotensin convert enzyme inhibitor AT-1 angiotensin II receptor blocker lead reduction proteinuria , main prognostic marker chronic kidney disease progression .</brief_summary>
	<brief_title>Optimalization Nephroprotection Using Atorvastatin ( Sortis )</brief_title>
	<detailed_description>The renin-angiotensin-aldosterone system ( RAAS ) play important role progression chronic kidney disease ( CKD ) , inhibition RAAS angiotensin-converting enzyme inhibitor ( ACEI ) angiotensin II type 1 receptor blocker ( ARB ) may retard CKD progression . Dual pharmacological blockade RAAS ACEI ARB recommend standard renoprotective management least patient nondiabetic proteinuric CKD . However , neither ACEI ARB , even high dos concomitant usage , abrogate progression CKD completely . Innovative approach need keep patient CKD dialysis . Additional statin ( Atorvastatin ) pathway may prove beneficial therapeutic concept.Given fact additional administration statin combination treatment ACEI ARB , may provide additional renal protection . To shed light issue , perform randomise open control study evaluate influence triple therapy ACEI and/orARB statin surrogate marker kidney injury , i.e . proteinuria , marker tubular involvement kidney fibrosis .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Chronic kidney disease Stable proteinuria 300 mg/24 hour ( variation 25 % last 6 month ) Normal slightly impair stable renal function define serum creatinine level 1.7 mg/dl ( eGFR &gt; 45 ml/min ) Nephrotic syndrome Steroids immunosuppressive treatment minimum six month study Diabetes mellitus Potassium serum level &gt; 5.1 mEq/L Albumin serum level &lt; 2.0mg/dL Creatinine serum level &gt; 2 mg/dl Current diagnosis heart failure New York Heart Association ( NYHA ) Class IIIV Clinically significant valvular heart disease second third degree heart block without pacemaker History hypertensive encephalopathy , cerebrovascular accident transient ischemic cerebral attack History myocardial infarction , unstable angina pectoris , coronary bypass surgery , percutaneous coronary intervention History malignancy include leukemia lymphoma ( basal cell skin carcinoma ) within past five year Pregnant nursing woman Any surgical medical condition might significantly alter absorption , distribution , metabolism , excretion study drug . History alcohol abuse NSAID abuse ( 2 dos per week ) Known suspect contraindication study medication , include history allergy ACE inhibitor , AT1 receptor blocker atorvastatin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Proteinuria ,</keyword>
	<keyword>atorvastatin</keyword>
</DOC>